The Nuvaxovid Covid-19 vaccine uses a long-established protein-based technology that is an alternative to the messenger ribonucleic acid (mRNA) vaccines by Pfizer-BioNTech and Moderna. — Nuvo picture via Reuters
Monday, 19 Sep 2022 10:31 PM MYT
SINGAPORE, Sept 19 — More than 18,000 doses of Nuvaxovid vaccine have been administered as of Aug 31, with 28 reports of adverse reactions, of which 82 per cent — or 23 cases — were not serious, said the Health Sciences Authority (HSA) in its latest safety update on Covid-19 vaccines today.
Allergic reactions reported from this vaccine included rash and eyelid swelling, numbness, dizziness, chest pains and vasculitis, which is an inflammation of blood vessels.
These were largely consistent with what were reported in the clinical studies or with other Covid-19 vaccines, said HSA.
Of the five serious cases reported, four patients suffered anaphylaxis — a potentially life-threatening allergic reaction — and one had a “serious allergic reaction” from the Nuvaxovid vaccine, which has been available here since May 18.
All five patients have recovered from these reactions, added HSA in its 13th vaccine safety update which covers the period Dec 30, 2020 to Aug 31, 2022.
The authority said these rea...